中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 41 Issue 10
Oct.  2025
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2025  >  41(10): 2141-2148

Research advances in therapeutic drugs for hepatic fibrosis

DOI: 10.12449/JCH251027

  • Central Laboratory，The Affiliated Hospital of Chengdu University of Traditional Chinese Medicine，Chengdu 610072，China

Research funding:

General Project of National Natural Science Foundation of China (82274323);

Key Research and Development Project of Sichuan Provincial Department of Science and Technology (2024YFFK0150);

Joint Innovation Fund of Health Commission of Chengdu and Chengdu University of Traditional Chinese Medicine (WXLH202403100)

More Information
  • Corresponding author: LI Hui， 1400124746@qq.com （ORCID： 0000-0002-5919-1396）
  • Received Date: 2025-03-19
  • Accepted Date: 2025-06-09
  • Published Date: 2025-10-25
    Abstract
  • Hepatic fibrosis is a chronic pathological condition characterized by hepatic stellate cell activation and excessive deposition of extracellular matrix， which would progress to liver cirrhosis and even hepatocellular carcinoma. Therefore， reversal of hepatic fibrosis is of great importance for improving quality of life and prolonging survival time. Currently， various therapeutic drugs for hepatic fibrosis have entered the stage of clinical trial. This article reviews the research advances in therapeutic drugs for hepatic fibrosis in the recent years， in order to provide insights into the treatment of hepatic fibrosis and future research directions for drugs.

     

    • FullText(HTML)
  • loading
    • References(56)
  • [1]
    MOON AM, SINGAL AG, TAPPER EB. Contemporary epidemiology of chronic liver disease and cirrhosis[J]. Clin Gastroenterol Hepatol, 2020, 18( 12): 2650- 2666. DOI: 10.1016/j.cgh.2019.07.060.
    [2]
    BERUMEN J, BAGLIERI J, KISSELEVA T, et al. Liver fibrosis: Pathophysiology and clinical implications[J]. WIREs Mech Dis, 2021, 13( 1): e1499. DOI: 10.1002/wsbm.1499.
    [3]
    LIAO ZH, XIE ZY. Research progress in molecular mechanism of hepatic fibrosis and related therapeutic targets[J]. J Jilin Univ(Med Edit), 2024, 50( 5): 1450- 1456. DOI: 10.13481/j.1671-587X.20240532.

    廖昭辉, 谢正元. 肝纤维化发病的分子机制及其相关治疗靶点的研究进展[J]. 吉林大学学报(医学版), 2024, 50( 5): 1450- 1456. DOI: 10.13481/j.1671-587X.20240532.
    [4]
    BOGOMOLOV PO, IVASHKIN VT, BUEVEROV AO, et al. Efficacy and safety of bulevirtide in patients with chronic hepatitis D and compensated cirrhosis[J]. Ter Arkh, 2021, 93( 11): 1290- 1299. DOI: 10.26442/00403660.2021.11.201163.
    [5]
    CHO Y, RHEE H, KIM YE, et al. Ezetimibe combination therapy with statin for non-alcoholic fatty liver disease: An open-label randomized controlled trial(ESSENTIAL study)[J]. BMC Med, 2022, 20( 1): 93. DOI: 10.1186/s12916-022-02288-2.
    [6]
    HOOSHMAND GHARABAGH L, SHARGH A, MOHAMMAD HOSSEINI AZAR MR, et al. Comparison between the effect of Empagliflozin and Pioglitazone added to metformin in patients with type 2 diabetes and nonalcoholic fatty liver disease[J]. Clin Res Hepatol Gastroenterol, 2024, 48( 3): 102279. DOI: 10.1016/j.clinre.2023.102279.
    [7]
    LI X, MENG Y, YANG XS, et al. ACEI attenuates the progression of CCl4-induced rat hepatic fibrogenesis by inhibiting TGF-beta1, PDGF-BB, NF-kappaB and MMP-2, 9[J]. World J Gastroenterol, 2005, 11( 31): 4807- 4811. DOI: 10.3748/wjg.v11.i31.4807.
    [8]
    MOSTAFA TM, EL-AZAB GA, BADRA GA, et al. Effect of candesartan and ramipril on liver fibrosis in patients with chronic hepatitis C viral infection: A randomized controlled prospective study[J]. Curr Ther Res Clin Exp, 2021, 95: 100654. DOI: 10.1016/j.curtheres.2021.100654.
    [9]
    WANG ML, ZHANG QD, QU Y, et al. Experimental study of hydronidone in the treatment of hepatic fibrosis induced by carbon tetrachloride in mice[J]. Int J Dig Dis, 2019, 39( 3): 175- 180, 231. DOI: 10.3969/j.issn.1673-534X.2019.03.008.

    王美玲, 张启迪, 曲颖, 等. 羟尼酮治疗四氯化碳诱导小鼠肝纤维化的实验研究[J]. 国际消化病杂志, 2019, 39( 3): 175- 180, 231. DOI: 10.3969/j.issn.1673-534X.2019.03.008.
    [10]
    CAI XB, LIU XH, XIE W, et al. Hydronidone for the treatment of liver fibrosis related to chronic hepatitis B: A phase 2 randomized controlled trial[J]. Clin Gastroenterol Hepatol, 2023, 21( 7): 1893- 1901. DOI: 10.1016/j.cgh.2022.05.056.
    [11]
    BARCHETTA I, CIMINI FA, CAVALLO MG. Vitamin D and metabolic dysfunction-associated fatty liver disease(MAFLD): An update[J]. Nutrients, 2020, 12( 11): 3302. DOI: 10.3390/nu12113302.
    [12]
    EBRAHIMPOUR-KOUJAN S, SOHRABPOUR AA, GIOVANNUCCI E, et al. Effects of vitamin D supplementation on liver fibrogenic factors, vitamin D receptor and liver fibrogenic microRNAs in metabolic dysfunction-associated steatotic liver disease(MASLD) patients: An exploratory randomized clinical trial[J]. Nutr J, 2024, 23( 1): 24. DOI: 10.1186/s12937-024-00911-x.
    [13]
    CHIANG JYL, FERRELL JM. Discovery of farnesoid X receptor and its role in bile acid metabolism[J]. Mol Cell Endocrinol, 2022, 548: 111618. DOI: 10.1016/j.mce.2022.111618.
    [14]
    RINELLA ME, LIEU HD, KOWDLEY KV, et al. A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis[J]. Hepatology, 2024, 79( 3): 674- 689. DOI: 10.1097/HEP.0000000000000607.
    [15]
    HARRISON SA, ABDELMALEK MF, NEFF G, et al. Aldafermin in patients with non-alcoholic steatohepatitis(ALPINE 2/3): A randomised, double-blind, placebo-controlled, phase 2b trial[J]. Lancet Gastroenterol Hepatol, 2022, 7( 7): 603- 616. DOI: 10.1016/S2468-1253(22)00017-6.
    [16]
    TRAUNER M, BOWLUS CL, GULAMHUSEIN A, et al. Safety and sustained efficacy of the farnesoid X receptor(FXR) agonist cilofexor over a 96-week open-label extension in patients with PSC[J]. Clin Gastroenterol Hepatol, 2023, 21( 6): 1552- 1560. DOI: 10.1016/j.cgh.2022.07.024.
    [17]
    QIU YY, ZHANG J, ZENG FY, et al. Roles of the peroxisome proliferator-activated receptors(PPARs) in the pathogenesis of nonalcoholic fatty liver disease(NAFLD)[J]. Pharmacol Res, 2023, 192: 106786. DOI: 10.1016/j.phrs.2023.106786.
    [18]
    WANG YM, LI HQ, GAO H, et al. Effect of chiglitazar and sitagliptin on glucose variations, insulin resistance and inflammatory-related biomarkers in untreated patients with type 2 diabetes[J]. Diabetes Res Clin Pract, 2022, 183: 109171. DOI: 10.1016/j.diabres.2021.109171.
    [19]
    FRANCQUE SM, HODGE A, BOURSIER J, et al. Phase 2, open-label, rollover study of cenicriviroc for liver fibrosis associated with metabolic dysfunction-associated steatohepatitis[J]. Hepatol Commun, 2024, 8( 2): e0335. DOI: 10.1097/HC9.0000000000000335.
    [20]
    OUCHI H, MIZUTANI Y, YOSHIMURA K, et al. Anti-inflammatory and antifibrotic effects of CBP/β-catenin inhibitor for hepatocytes: Small molecular inhibitor, OP-724 possibly improves liver function[J]. Med Mol Morphol, 2023, 56( 2): 94- 105. DOI: 10.1007/s00795-022-00343-8.
    [21]
    KIMURA K, KANTO T, SHIMODA S, et al. Safety, tolerability, and anti-fibrotic efficacy of the CBP/β-catenin inhibitor PRI-724 in patients with hepatitis C and B virus-induced liver cirrhosis: An investigator-initiated, open-label, non-randomised, multicentre, phase 1/2a study[J]. EBioMedicine, 2022, 80: 104069. DOI: 10.1016/j.ebiom.2022.104069.
    [22]
    KIMURA M, OGAWA E, HARADA K, et al. Feasibility, safety and tolerability of the CREB-binding protein/β-catenin inhibitor OP-724 in patients with advanced primary biliary cholangitis: An investigator-initiated, open-label, non-randomised, two-centre, phase 1 study[J]. BMJ Open Gastroenterol, 2022, 9( 1): e001001. DOI: 10.1136/bmjgast-2022-001001.
    [23]
    KIMURA K, TANUMA J, KIMURA M, et al. Safety and tolerability of OP-724 in patients with haemophilia and liver cirrhosis due to HIV/HCV coinfection: An investigator-initiated, open-label, non-randomised, single-centre, phase I study[J]. BMJ Open Gastroenterol, 2024, 11( 1): e001341. DOI: 10.1136/bmjgast-2023-001341.
    [24]
    URE DR, TREPANIER DJ, MAYO PR, et al. Cyclophilin inhibition as a potential treatment for nonalcoholic steatohepatitis(NASH)[J]. Expert Opin Investig Drugs, 2020, 29( 2): 163- 178. DOI: 10.1080/13543784.2020.1703948.
    [25]
    KUO J, BOBARDT M, CHATTERJI U, et al. A pan-cyclophilin inhibitor, CRV431, decreases fibrosis and tumor development in chronic liver disease models[J]. J Pharmacol Exp Ther, 2019, 371( 2): 231- 241. DOI: 10.1124/jpet.119.261099.
    [26]
    HARRISON SA, MAYO PR, HOBBS TM, et al. Rencofilstat, a cyclophilin inhibitor: A phase 2a, multicenter, single-blind, placebo-controlled study in F2/F3 NASH[J]. Hepatol Commun, 2022, 6( 12): 3379- 3392. DOI: 10.1002/hep4.2100.
    [27]
    WESTON CJ, SHEPHERD EL, CLARIDGE LC, et al. Vascular adhesion protein-1 promotes liver inflammation and drives hepatic fibrosis[J]. J Clin Invest, 2015, 125( 2): 501- 520. DOI: 10.1172/JCI73722.
    [28]
    HIRSCHFIELD GM, ARNDTZ K, KIRKHAM A, et al. Vascular adhesion protein-1 blockade in primary sclerosing cholangitis: Open-label, multicenter, single-arm, phase II trial[J]. Hepatol Commun, 2024, 8( 5): e0426. DOI: 10.1097/HC9.0000000000000426.
    [29]
    AOYAMA T, PAIK YH, WATANABE S, et al. Nicotinamide adenine dinucleotide phosphate oxidase in experimental liver fibrosis: GKT137831 as a novel potential therapeutic agent[J]. Hepatology, 2012, 56( 6): 2316- 2327. DOI: 10.1002/hep.25938.
    [30]
    INVERNIZZI P, CARBONE M, JONES D, et al. Setanaxib, a first-in-class selective NADPH oxidase 1/4 inhibitor for primary biliary cholangitis: A randomized, placebo-controlled, phase 2 trial[J]. Liver Int, 2023, 43( 7): 1507- 1522. DOI: 10.1111/liv.15596.
    [31]
    MASLENNIKOV R, POLUEKTOVA E, ZOLNIKOVA O, et al. Gut microbiota and bacterial translocation in the pathogenesis of liver fibrosis[J]. Int J Mol Sci, 2023, 24( 22): 16502. DOI: 10.3390/ijms242216502.
    [32]
    ISRAELSEN M, MADSEN BS, TORP N, et al. Rifaximin-α for liver fibrosis in patients with alcohol-related liver disease(GALA-RIF): A randomised, double-blind, placebo-controlled, phase 2 trial[J]. Lancet Gastroenterol Hepatol, 2023, 8( 6): 523- 532. DOI: 10.1016/S2468-1253(23)00010-9.
    [33]
    BAI GP, ZHANG RH, YAN GH, et al. The effect of modified turtle shell decoction on the expression of TGFβ1, Smad3 and Smad7 in rat hepatic stellate cell[J]. Immunol J, 2017, 33( 9): 777- 782. DOI: 10.13431/j.cnki.immunol.j.20170137.

    柏干苹, 张荣华, 闫国和, 等. 鳖甲煎改良方对肝星状细胞生长及TGFβ1、Smad3与Smad7表达的影响[J]. 免疫学杂志, 2017, 33( 9): 777- 782. DOI: 10.13431/j.cnki.immunol.j.20170137.
    [34]
    CHI X, CHENG DY, SUN X, et al. Efficacy of Biejiajian pill on intestinal microbiota in patients with hepatitis B cirrhosis/liver fibrosis: A randomized double-blind controlled trial[J]. Chin J Integr Med, 2023, 29( 9): 771- 781. DOI: 10.1007/s11655-023-3542-2.
    [35]
    ESCOUTO GS, PORT GZ, TOVO CV, et al. Probiotic supplementation, hepatic fibrosis, and the microbiota profile in patients with nonalcoholic steatohepatitis: A randomized controlled trial[J]. J Nutr, 2023, 153( 7): 1984- 1993. DOI: 10.1016/j.tjnut.2023.05.019.
    [36]
    CLARK VC, STRANGE C, STRNAD P, et al. Fazirsiran for adults with alpha-1 antitrypsin deficiency liver disease: A phase 2 placebo controlled trial(SEQUOIA)[J]. Gastroenterology, 2024, 167( 5): 1008- 1018. DOI: 10.1053/j.gastro.2024.06.028.
    [37]
    LOOMBA R, SANYAL AJ, NAKAJIMA A, et al. Pegbelfermin in patients with nonalcoholic steatohepatitis and stage 3 fibrosis(FALCON 1): A randomized phase 2b study[J]. Clin Gastroenterol Hepatol, 2024, 22( 1): 102- 112. DOI: 10.1016/j.cgh.2023.04.011.
    [38]
    HARRISON SA, FRIAS JP, NEFF G, et al. Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis(HARMONY): A multicentre, randomised, double-blind, placebo-controlled, phase 2b trial[J]. Lancet Gastroenterol Hepatol, 2023, 8( 12): 1080- 1093. DOI: 10.1016/S2468-1253(23)00272-8.
    [39]
    HARRISON SA, BEDOSSA P, GUY CD, et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis[J]. N Engl J Med, 2024, 390( 6): 497- 509. DOI: 10.1056/NEJMoa2309000.
    [40]
    LOOMBA R, HARTMAN ML, LAWITZ EJ, et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis[J]. N Engl J Med, 2024, 391( 4): 299- 310. DOI: 10.1056/NEJMoa2401943.
    [41]
    LOOMBA R, ABDELMALEK MF, ARMSTRONG MJ, et al. Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: A randomised, placebo-controlled phase 2 trial[J]. Lancet Gastroenterol Hepatol, 2023, 8( 6): 511- 522. DOI: 10.1016/S2468-1253(23)00068-7.
    [42]
    LAWITZ EJ, FRAESSDORF M, NEFF GW, et al. Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis[J]. J Hepatol, 2024, 81( 5): 837- 846. DOI: 10.1016/j.jhep.2024.06.003.
    [43]
    SANYAL AJ, BEDOSSA P, FRAESSDORF M, et al. A phase 2 randomized trial of survodutide in MASH and fibrosis[J]. N Engl J Med, 2024, 391( 4): 311- 319. DOI: 10.1056/NEJMoa2401755.
    [44]
    PERVA IT, SIMINA IE, BENDE R, et al. Use of a micronutrient cocktail to improve metabolic dysfunction-associated steatotic liver disease(MASLD) in adults with obesity: A randomized, double-blinded pilot clinical trial[J]. Medicina(Kaunas), 2024, 60( 8): 1366. DOI: 10.3390/medicina60081366.
    [45]
    ARMANDI A, BESPALJKO H, MANG A, et al. Short-term reduction of dietary gluten improves metabolic-dysfunction associated steatotic liver disease: A randomised, controlled proof-of-concept study[J]. Aliment Pharmacol Ther, 2024, 59( 10): 1212- 1222. DOI: 10.1111/apt.17941.
    [46]
    SILVA-CARVALHO R, BALTAZAR F, ALMEIDA-AGUIAR C. Propolis: A complex natural product with a plethora of biological activities that can be explored for drug development[J]. Evid Based Complement Alternat Med, 2015, 2015: 206439. DOI: 10.1155/2015/206439.
    [47]
    NIKBAF-SHANDIZ M, TUTUNCHI H, KHOSHBATEN M, et al. Propolis supplementation in obese patients with non-alcoholic fatty liver disease: Effects on glucose homeostasis, lipid profile, liver function, anthropometric indices and meta-inflammation[J]. Food Funct, 2022, 13( 22): 11568- 11578. DOI: 10.1039/d2fo01280d.
    [48]
    WU LC, HO JA, SHIEH MC, et al. Antioxidant and antiproliferative activities of Spirulina and Chlorella water extracts[J]. J Agric Food Chem, 2005, 53( 10): 4207- 4212. DOI: 10.1021/jf0479517.
    [49]
    STINE JG, WELLES JE, KEATING S, et al. Serum fibroblast growth factor 21 is markedly decreased following exercise training in patients with biopsy-proven nonalcoholic steatohepatitis[J]. Nutrients, 2023, 15( 6): 1481. DOI: 10.3390/nu15061481.
    [50]
    HARRIS SJ, SMITH N, HUMMER B, et al. Exercise training improves serum biomarkers of liver fibroinflammation in patients with metabolic dysfunction-associated steatohepatitis[J]. Liver Int, 2024, 44( 2): 532- 540. DOI: 10.1111/liv.15769.
    [51]
    GUO XL, JIA ZS, ZHANG J. Molecular mechanisms of traditional Chinese medicine in reversing liver fibrosis[J]. J Clin Hepatol, 2025, 41( 1): 170- 175. DOI: 10.12449/JCH250126.

    郭晓玲, 贾战生, 张静. 中药逆转肝纤维化的分子机制[J]. 临床肝胆病杂志, 2025, 41( 1): 170- 175. DOI: 10.12449/JCH250126.
    [52]
    LI MQ, LIU FR, GUO XJ, et al. Clinical observation of Kucai paste combined with Entecavir in the treatment of chronic hepatitis B liver fibrosis[J]. J Changchun Univ Chin Med, 2024, 40( 3): 301- 305. DOI: 10.13463/j.cnki.cczyy.2024.03.015.

    李梦琪, 刘繁荣, 郭新建, 等. 苦菜膏联合恩替卡韦治疗慢性乙型肝炎肝纤维化的临床观察[J]. 长春中医药大学学报, 2024, 40( 3): 301- 305. DOI: 10.13463/j.cnki.cczyy.2024.03.015.
    [53]
    Liver Disease Committee, Chinese Association of Integrative Medicine. Guidelines for the diagnosis and treatment of liver fibrosis in integrative medicine practice(2019)[J]. J Clin Hepatol, 2019, 35( 7): 1444- 1449. DOI: 10.3969/j.issn.1001-5256.2019.07.007.

    中国中西医结合学会肝病专业委员会. 肝纤维化中西医结合诊疗指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35( 7): 1444- 1449. DOI: 10.3969/j.issn.1001-5256.2019.07.007.
    [54]
    XIAO HM, SHI MJ, JIANG JM, et al. Efficacy and safety of AnluoHuaxian pills on chronic hepatitis B with normal or minimally elevated alanine transaminase and early liver fibrosis: A randomized controlled trial[J]. J Ethnopharmacol, 2022, 293: 115210. DOI: 10.1016/j.jep.2022.115210.
    [55]
    PENG DT, XING YF, CHEN L, et al. Clinical study of Ruangan granules combined with Entecavir in the treatment of severe hepatitis B fibrosis[J]. Lishizhen Med Mater Med Res, 2019, 30( 8): 1934- 1936. DOI: 10.3969/j.issn.1008-0805.2019.08.050.

    彭得倜, 邢宇锋, 陈亮, 等. 软肝颗粒联合恩替卡韦治疗乙肝重度肝纤维化的临床研究[J]. 时珍国医国药, 2019, 30( 8): 1934- 1936. DOI: 10.3969/j.issn.1008-0805.2019.08.050.
    [56]
    XING YF, ZHONG WC, PENG DT, et al. Chinese herbal formula Ruangan granule enhances the efficacy of entecavir to reverse advanced liver fibrosis/early cirrhosis in patients with chronic HBV infection: A multicenter, randomized clinical trial[J]. Pharmacol Res, 2023, 190: 106737. DOI: 10.1016/j.phrs.2023.106737.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (64) PDF downloads(21) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return